

# **Pathogenesis of Atherosclerosis: review**

## **Abstract**

The goal of this research was to examine the mechanisms of atherosclerosis development, such as endothelial dysfunction, fatty streak formation, fibrous plaque formation, and plaque rupture. This article takes a thorough look at the pathophysiology of atherosclerosis, addressing the pathological and biochemical mechanisms of atherosclerotic plaque development and growth.

## *Keywords*

*Atherosclerosis, endothelial dysfunction, foam cells, inflammation, LDL.*

## **1. Introduction**

Atherosclerosis is derived from the Greek term Athero, which means "gruel" (1). Marchand coined the term "atherosclerosis" to describe the relationship between fatty degeneration and arterial stiffness (2). Atherosclerosis is a systemic disease of large and medium-sized arteries characterized by the buildup of lipids and fibrous materials in the artery wall, as well as contributing immune cells, smooth muscle cells (SMC), and endothelial cells, resulting in plaques and, in some cases, stenosis. The process's beginning is unknown, although it is most likely the consequence of an interaction between multiple distinct processes, including plasma lipid levels, blood flow mechanics (shear stress and turbulent flow), and genetic predispositions. Lipoprotein retention, inflammatory cell recruitment, foam cell formation, apoptosis and necrosis, migration of smooth muscle cells (SMCs) and their proliferation and secretion of extracellular matrix (ECM) components (such as collagen, elastin, and proteoglycans), calcification, neovessel formation, arterial remodeling, fibrous cap rupture, and thrombosis (3,4).

It is the main cause of illness and death in the United States and the rest of the Western world. Cardiovascular disease (CVD) is still the leading cause of mortality in the modern age. CVD was responsible for 17 million fatalities in 2008. More than 3 million of these fatalities occurred in persons under the age of 60 and may have been avoided in major part (5). There are rising disparities across nations and socioeconomic classes in the prevalence and outcome of CVD.

## **2. The Origin of Atherosclerosis and the Formation of Fatty Streaks**

In the past two decades, research has shown that atherosclerosis is a persistent inflammatory condition, contrary to popular belief that atherosclerosis is a degenerative illness caused by the aging process (6). Atherosclerosis begins with endothelial dysfunction, followed by LDL retention and modification in the intima (7,8). Modified LDLs, in conjunction with other atherogenic factors, stimulate EC activation, resulting in monocyte recruitment into the

intima. Modified LDLs are rapidly captured by differentiated monocytes and VSMC, promoting foam cell production (9,10). Furthermore, various inflammatory signaling pathways are engaged, permitting the creation of fatty streaks, which is the initial symptom of atherosclerosis and is characterized by a significant buildup of lipids both inside the cells (macrophages and VSMC) and the extracellular media. Fatty streaks progress to atherosclerotic plaques, which are comprised of three components: inflammatory cells, smooth muscle cells, a fibrous component of connective tissue, and a fat component of lipids (11).

When endothelial dysfunction occurs, fatty streaks form because of matrix proteoglycan exposure and loss of the confluent elastic layer of the blood vessel lumen, which is typically detected around arterial bifurcation locations (12). Recent findings point to hypercholesterolemia as a primary cause of endothelial dysfunction by altering endothelial permeability, enabling LDL-c to migrate into the arterial wall (13). The macrophage receptor recognition shift toward LDL owing to oxidative alteration enables absorption of LDL by monocyte-derived macrophages through SR that are not controlled by cell cholesterol concentration and may bind Ox-LDL and native lipoproteins (14,15) Due to SR's action, macrophages will accumulate lipids in their cytoplasm, giving them a foamy appearance; these cells are called foam cells and are the hallmark of fatty streak (16–18).

### **2.1. Low-density lipoprotein cholesterol trapping and oxidation (LDL-c)**

High circulating amounts of cholesterol carried by apolipoprotein B100-containing-LDL were shown to be a required step for LDL-c transport across vascular endothelium and LDL entrapment inside the blood vessel wall (19). Lipoproteins penetrate the artery wall through the defective endothelium that surrounds the vessel lumen, and this is followed by the entrance of monocytes and other inflammatory cells (20). Lipoproteins are able to pass through the endothelium barrier, which causes LDLs to accumulate and be deposited in the intima (21).

Once trapped inside the arterial wall, LDL-c undergoes lipid peroxidation because of locally released reactive oxygen species (ROS), also known as free radicals (14,22). ROS are described as oxygen molecules (O<sub>2</sub>) that take a single electron and undergo transformation into extremely reactive radicals that harm cellular lipids, proteins, and DNA (23). ROS, myeloperoxidase, lipoperoxidase, and nicotinamide adenine dinucleotide phosphate (NADH/NADPH) oxidases are all involved in the LDL peroxidation process (19,22). Oxidized LDLs include oxidized lipids and breakdown products that promote atherosclerotic plaque formation (24,25). Endothelial cells express more vasoconstricting factors (mostly endothelin-1) and less vasodilating factors (especially nitric oxide).

According to (18) and (26), trapped LDL oxidation takes place in two steps:

1. Oxidation of LDL lipids before monocyte migration to artery wall, with no change in Apo B100 protein.
2. Further oxidation of LDL lipids and modification of Apo B100 occur after monocyte recruitment to the lesion and conversion to macrophages. This is followed by the uptake of native LDL as well as Ox-LDL by macrophages via scavenger receptors (SR) and other suggested pathways such as sortilin protein receptors and fluid-phase pinocytosis.

### **2.3. Recruitment of Monocytes and Formation of Foam Cells**

Monocytes develop into macrophages inside the intima and internalize atherogenic lipoproteins through scavenger receptors, among which SR-A and CD36 have been shown to play quantitatively important roles in experimental atherosclerosis. The formation of lipid-loaded macrophages (foam cells) containing enormous levels of cholesteryl esters is a feature of both early and late atherosclerotic lesions (27). Monocytes develop into macrophages in the

intima, where they may be polarized to the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype (28). Nonetheless, macrophages are sensitive to changes in the inflammatory environment and may flip their phenotype from pro-inflammatory to anti-inflammatory in response to new signals.

Macrophages also express molecules that increase and amplify leukocyte adherence and migration to the artery wall, such as vascular cell adhesion molecule (VCAM), intracellular adhesion molecule (ICAM), and monocyte chemoattractant protein 1 [MCP-1] (29,30). Upregulation of VCAM-1, ICAM-1, selectins and chemo-attractants such as lipids, platelets-activating factor, and chemokines such as interleukin-8 and MCP-1 are all associated with oxidized LDL (14,31). Once in the subendothelial space, monocytes develop macrophage characteristics in response to macrophage-colony stimulating factor (32) and express SR [A, B1, CD36, CD68, lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1)] that binds modified lipoproteins such as Ox-LDL, native lipoproteins, and anionic phospholipids (13,33)

## **2.4. Atherosclerosis endothelial dysfunction and VSMC Contribution to Foam Cell Population**

Li (34) revealed that VCAM-1 expression on endothelial surfaces was a critical early stage in the etiology of atherosclerosis. Increased cellular adhesion and accompanying endothelial dysfunction subsequently "sets the scene" for inflammatory cell recruitment, cytokine release, and lipid recruitment into the atherosclerotic plaque. VCAM-1 expression increases monocyte and T-cell recruitment to sites of endothelial injury; subsequent release of MCP-1 by leukocytes magnifies the inflammatory cascade by recruiting additional leukocytes, activating leukocytes in the media, and causing recruitment and proliferation of smooth muscle cells (35). VSMCs in the intima may also ingest oxLDL in an unregulated manner through several scavenger receptors such as SR-A, CD36, and LOX-1 (36–38). At least half of the foam cells in the human coronary intima are VSMC-derived rather than monocyte-derived, demonstrating the role of VSMCs in the development of atherosclerosis (39).

Endothelial cells over-express adhesion molecules in response to turbulent flow in the presence of an unfavorable serum lipid profile, which is how atherosclerosis is likely to begin (35). Endothelial dysfunction results from disturbed vascular homeostasis (40–42). When ECs lose homeostasis, vessel walls are prone to vasoconstriction, lipid infiltration, leukocyte adhesion, platelet activation, and oxidative stress (43,44). Together, they trigger an inflammatory response that leads to the formation of fatty streaks (41,42). Endothelial dysfunction also contributes to plaque formation and rupture in later stages of atherosclerosis (42). Endothelial dysfunction is an early sign of atherogenesis (45,46).

## **3. Fibrous Plaque Development**

A thick fibrous covering containing VSMCs covers and stabilizes the vulnerable plaque (47). The necrotic core and fibrous cap are the distinguishing features of advanced atherosclerosis (48), and atheroma plaque regression is rare at this point (49,50).

### **3.1. Fibrous Cap Thinning**

Any action that reduces the production of fibrous cap collagen by intimal fibroblast-like smooth muscle cells (SMCs) and/or contributes to cap collagen breakdown would be predicted to encourage the development of plaques prone to rupture (51). Vulnerable plaques exhibit indications of SMC mortality and reduced SMC levels, and in vitro findings demonstrate that macrophages may induce SMC apoptosis by activating the Fas apoptotic pathway and secreting proapoptotic TNF $\alpha$  and nitric oxide (52). MMPs (matrix metalloproteinases) produced by macrophages may also be implicated in fibrous cap thinning. MMPs are a protease-activated enzyme family that may destroy diverse extracellular matrix (ECM) proteins (51).

The fibrous cap is a subendothelial barrier that separates the vascular lumen from the atherosclerotic necrotic core, which is composed of VSMCs that have migrated to the luminal side of the artery and extracellular matrix (ECM) produced from VSMCs (53,54). The fibrous cap's job is to act as a structural support to prevent the exposure of prothrombotic material from the core, which would otherwise cause thrombosis (53).

In atherosclerosis, VSMCs from the tunica media move to the intima in response to growth factors generated by foam cells (VSMC- or macrophage-derived) or intima ECs (54–57). Furthermore, IL-1 generated by macrophages increases VSMC endogenous PDGF production and, once in the intima, autocrinally leads to their proliferation (58,59). VSMCs with a synthetic phenotype boost the synthesis of ECM components such as interstitial collagen, elastin, and proteoglycans in addition to migration and subsequent proliferation (3,4,57,60) These proliferating VSMCs, in conjunction with ECM synthesis, produce a fibrous cap that surrounds and prevents the rupture of the growing atherosclerotic plaque (61).

### **3.2. Necrotic Core**

The necrotic core is a second key characteristic of hazardous plaques that leads to inflammation, thrombosis, proteolytic plaque disintegration, and physical stress on the fibrous cap (Virmani et al., 2002). Necrotic cores form because of advanced lesional macrophage apoptosis combined with poor phagocytic clearance (or efferocytosis) of the apoptotic macrophages in advanced plaques (Tabas, 2010a). This combination is critical: although macrophage mortality occurs in early atherosclerotic lesions, efferocytic clearance is effective, resulting in reductions in lesion cellularity, inflammation, and plaque development rather than an increase in plaque necrosis.

### **3.3. Plaque Calcification**

Another sign of advanced atherosclerosis is calcification of atheroma plaques. It appears as a bone-like structure inside the plaque and begins in inflammatory areas with a local reduction in collagen fibers (62)(63). During the development of atherosclerosis, pericytes (64) and VSMCs (65,66) transdifferentiate into osteoblast-like phenotypes, gaining the ability to form a mineralized matrix and leading to calcium deposits, as seen in bone tissue (67–69). This all adds to microcalcifications, which are the first step of the vascular calcification cascade in both the intima and the media (62,70). Microcalcifications eventually progress to bigger calcifications that extend from the necrotic core's bottom to the surrounding matrix (66).

## **4. Plaque Rupture and Thrombus Formation**

Plaque rupture is defined as "a plaque with profound damage with a true hole or breach in the fibrous cap that had isolated its lipid-rich atheromatous core from the flowing blood, revealing the plaque's thrombogenic core" (71). The most prevalent cause of coronary artery thrombosis is this. When the plaque fissures or ruptures, blood enters the subendothelial area, causing a coagulation process to cover the wound (4,72). Platelets first bind to subendothelial collagen and become activated, and additional platelets are then recruited and aggregated in the location to commence wound healing (73). Concurrently, prothrombotic components of the lipid core are liberated and come into touch with plasma coagulating agents. More precisely, the tissue factor of the core combines with factor VII of the plasma, triggering the coagulation cascade that results in the synthesis of thrombin, a crucial intermediary in the creation of fibrin (61,74) Fibrin is an insoluble protein that creates networks of fibrin threads and fills the lesion with platelets, providing a stable and well-organized structure. The thrombus is the name given to this structure (75,76)

## **5. Conclusion**

In recent years, we have seen a rise in the burden of atherosclerotic disease, which adds to CVD risk and is becoming a worldwide pandemic. The study of atherosclerosis cellular and molecular biology mechanisms has yielded significant insights into the processes that contribute to atheroma formation and clinical symptoms of the disease. In industrialized nations, atherosclerosis is the major cause of mortality. A thorough knowledge of the causes and underlying mechanisms of pathogenesis will aid in the delineation of causes and the planning of creative treatment. More therapy possibilities will emerge as our understanding of the etiology of atherosclerosis improves.

## **6. DISCLAIMER**

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors. This study has not been published before or is not under consideration for publication elsewhere. Its publication is permitted by all authors and after accepted for publication it will not be submitted for publication anywhere else, in English or in any other language, without the written approval of the copyright holder. The authors grant this journal a license to publish the article and identify itself as the original publisher.

## References:

1. Virmani R, Burke A, Farb A, Kolodgie FD, Finn A V., Gold HK. Pathology of the vulnerable plaque. Handbook of the Vulnerable Plaque, Second Edition. 2007. p. 13–28.
2. Stary HC. Composition and classification of human atherosclerotic lesions. Vol. 421, Virchows Archiv A Pathological Anatomy and Histopathology. 1992. p. 277–90.
3. Glagov S, Jr WI, Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. Vol. 85, Circulation. 1992. p. 391–405.
4. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Vol. 114, Circulation Research. 2014. p. 1852–66.
5. Alexander RW, Dzau VJ. Vascular biology: the past 50 years. Vol. 102, Circulation. 2000.
6. Epstein FH, Fuster V, Badimon L, Badimon JJ, Chesebro JH. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes. Vol. 326, New England Journal of Medicine. 1992. p. 310–8.
7. Hermida N, Balligand JL. Low-density lipoprotein-cholesterol-induced endothelial dysfunction and oxidative stress: The role of statins. Vol. 20, Antioxidants and Redox Signaling. 2014. p. 1216–37.
8. Mundi S, Massaro M, Scoditti E, Carluccio MA, Van Hinsbergh VWM, Iruela-Arispe ML, et al. Endothelial permeability, LDL deposition, and cardiovascular risk factors-A review. Cardiovasc Res. 2018;114(1):35–52.
9. Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Vol. 424, Clinica Chimica Acta. 2013. p. 245–52.
10. Allahverdian S, Chehroudi AC, McManus BM, Abraham T, Francis GA. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Vol. 129, Circulation. 2014. p. 1551–9.
11. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Vol. 373, The Lancet. 2009. p. 1175–82.
12. Kwon GP, Schroeder JL, Amar MJ, Remaley AT, Balaban RS. Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Vol. 117, Circulation. 2008. p. 2919–27.

13. Bergheanu SC, Bodde MC, Jukema JW. Pathophysiology and treatment of atherosclerosis: Current view and future perspective on lipoprotein modification treatment. Vol. 25, Netherlands Heart Journal. 2017. p. 231–42.
14. Skopelitis E, Levisianou D, Lydataki H, Kougialis S. Oxidised Low Density Lipoprotein (LDL) Modification with Statin Therapy is Associated with Reduction in Carotid Stenosis. Carotid Artery Disease - From Bench to Bedside and Beyond. 2014.
15. Sakakura K, Nakano M, Otsuka F, Ladich E, Kolodgie FD, Virmani R. Pathophysiology of atherosclerosis plaque progression. Vol. 22, Heart Lung and Circulation. 2013. p. 399–411.
16. Itabe H. Oxidized low-density lipoproteins: What is understood and what remains to be clarified. Vol. 26, Biological and Pharmaceutical Bulletin. 2003. p. 1–9.
17. Zeller I, Srivastava S. Macrophage functions in atherosclerosis. Vol. 115, Circulation Research. 2014. p. e83–5.
18. Patel KM, Strong A, Tohyama J, Jin X, Morales CR, Billheimer J, et al. Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosis. Vol. 116, Circulation Research. 2015. p. 789–96.
19. Weber C, Noels H. Atherosclerosis: Current pathogenesis and therapeutic options. Vol. 17, Nature Medicine. 2011. p. 1410–22.
20. Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: Role of diffuse intimal thickening and extracellular matrix proteoglycans. Vol. 79, Cardiovascular Research. 2008. p. 14–23.
21. Colin S, Chinetti-Gbaguidi G, Staels B. Macrophage phenotypes in atherosclerosis. Vol. 262, Immunological Reviews. 2014. p. 153–66.
22. Hansson GK, Hermansson A. The immune system in atherosclerosis. Vol. 12, Nature Immunology. 2011. p. 204–12.
23. Lieberman, Michael, Peet A. Marks' basic medical biochemistry : a clinical approach. Vol. 4th, Basic medical biochemistry. 2017. p. 222–69.
24. Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Vol. 14, Nature Immunology. 2013. p. 812–20.
25. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: Does it hold for humans? Vol. 11, Trends in Cardiovascular Medicine. 2001. p. 93–102.
26. Tabas I, García-Cardeña G, Owens GK. Recent insights into the cellular biology of atherosclerosis. Vol. 209, Journal of Cell Biology. 2015. p. 13–22.
27. Glass, C. K., & Witztum JL. Atherosclerosis.
28. Shapouri-Moghaddam, A., Mohammadian, S., Vazini, H., Taghadosi, M., Esmaeili, S. A., Mardani, F., Seifi, B., Mohammadi, A., Afshari, J. T., & Sahebkar A. Macrophage plasticity, polarization, and function in health and disease - PubMed.
29. Wang D, Wang Z, Zhang L, Wang Y. Roles of Cells from the Arterial Vessel Wall in Atherosclerosis. Vol. 2017, Mediators of Inflammation. 2017.

30. Andreou DE, Andreadou I. Atherosclerosis: An inflammatory disease. Vol. 22, Pharmakeftiki. 2009. p. 83–96.
31. Randolph GJ. Mechanisms that regulate macrophage burden in atherosclerosis. Vol. 114, Circulation Research. 2014. p. 1757–71.
32. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Vol. 145, Cell. 2011. p. 341–55.
33. Pirillo, A., Norata, G. D., & Catapano AL. LOX-1, OxLDL, and atherosclerosis - PubMed.
34. Li H, Cybulsky MI, Gimbrone MA, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Vol. 13, Arteriosclerosis and Thrombosis. 1993. p. 197–204.
35. Crowther MA. Pathogenesis of Atherosclerosis | Hematology | American Society of Hematology [Internet]. Available from: <https://ashpublications.org/hematology/article/2005/1/436/19259/Pathogenesis-of-Atherosclerosis>
36. Beyea, M. M., Reaume, S., Sawyez, C. G., Edwards, J. Y., O’Neil, C., Hegele, R. A., Pickering, J. G., & Huff MW. The oxysterol 24(s),25-epoxycholesterol attenuates human smooth muscle-derived foam cell formation via reduced low-density lipoprotein uptake and enhanced cholesterol efflux - PubMed.
37. Ricciarelli R, Zingg JM, Azzi A. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Vol. 102, Circulation. 2000. p. 82–7.
38. Mietus-Snyder M, Gowri MS, Pitas RE. Class A Scavenger Receptor Up-regulation in Smooth Muscle Cells by Oxidized Low Density Lipoprotein. Vol. 275, Journal of Biological Chemistry. 2000. p. 17661–70.
39. Choi HY, Rahmani M, Wong BW, Allahverdian S, McManus BM, Pickering JG, et al. ATP-Binding cassette transporter a1 expression and apolipoprotein A-I binding are impaired in intima-type arterial smooth muscle cells. Vol. 119, Circulation. 2009. p. 3223–31.
40. Favero G, Paganelli C, Buffoli B, Rodella LF, Rezzani R. Endothelium and its alterations in cardiovascular diseases: Life style intervention. Vol. 2014, BioMed Research International. 2014.
41. Esper RJ, Nordaby RA, Vilariño JO, Paragano A, Cacharrón JL, Machado RA. Endothelial dysfunction: A comprehensive appraisal. Vol. 5, Cardiovascular Diabetology. 2006.
42. Sun HJ, Wu ZY, Nie XW, Bian JS. Role of endothelial dysfunction in cardiovascular diseases: The link between inflammation and hydrogen sulfide. Vol. 10, Frontiers in Pharmacology. 2020.
43. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Vol. 105, Circulation. 2002. p. 546–9.
44. Verma S, Buchanan MR, Anderson TJ. Endothelial Function Testing as a Biomarker of Vascular Disease. Vol. 108, Circulation. 2003. p. 2054–9.
45. Mudau M, Genis A, Lochner A, Strijdom H. Endothelial dysfunction: The early predictor of atherosclerosis. Vol. 23, Cardiovascular Journal of Africa. 2012. p. 222–31.
46. Berenji Ardestani S, Eftedal I, Pedersen M, Jeppesen PB, Nørregaard R, Matchkov V V. Endothelial dysfunction in small arteries and early signs of atherosclerosis in ApoE knockout rats. Vol. 10, Scientific Reports. 2020.

47. Durham AL, Speer MY, Scatena M, Giachelli CM, Shanahan CM. Role of smooth muscle cells in vascular calcification: Implications in atherosclerosis and arterial stiffness. Vol. 114, *Cardiovascular Research*. 2018. p. 590–600.
48. J. LA. Atherosclerosis - PubMed. Available from: <https://pubmed.ncbi.nlm.nih.gov/29939576/>
49. Fisher, E. A., Feig, J. E., Hewing, B., Hazen, S. L., & Smith JD. High-density lipoprotein function, dysfunction, and reverse cholesterol transport - PubMed.
50. Puri R, Nissen SE, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, et al. Factors underlying regression of coronary atheroma with potent statin therapy. Vol. 34, *European Heart Journal*. 2013.
51. K. J. Moore, I. Tabas. Macrophages in the pathogenesis of atherosclerosis. Vol. 145, *Cell*. 2011. p. 341–55.
52. Boyle JJ, Weissberg PL, Bennett MR. Tumor necrosis factor- $\alpha$  promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Vol. 23, *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2003. p. 1553–8.
53. Chamié D, Wang Z, Bezerra H, Rollins AM, Costa MA. Optical Coherence Tomography and Fibrous Cap Characterization. Vol. 4, *Current Cardiovascular Imaging Reports*. 2011. p. 276–83.
54. Watson MG, Byrne HM, Macaskill C, Myerscough MR. A two-phase model of early fibrous cap formation in atherosclerosis. Vol. 456, *Journal of Theoretical Biology*. 2018. p. 123–36.
55. Louis SF, Zahradka P. Vascular smooth muscle cell motility: From migration to invasion. Vol. 15, *Experimental and Clinical Cardiology*. 2010.
56. Stiko-Rahm A, Hultgårdh-Nilsson A, Regnström J, Hamsten A, Nilsson J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Vol. 12, *Arteriosclerosis, Thrombosis, and Vascular Biology*. 1992. p. 1099–109.
57. R. R. The pathogenesis of atherosclerosis--an update - PubMed.
58. Raines EW, Dower SK, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Vol. 243, *Science*. 1989. p. 393–6.
59. Forsyth EA, Aly HM, Neville RF, Sidawy AN, Panetta TF, DePippo P, et al. Proliferation and extracellular matrix production by human infragenicular smooth muscle cells in response to interleukin-1 $\beta$ . Vol. 26, *Journal of Vascular Surgery*. 1997. p. 1002–8.
60. Sorokin V, Vickneson K, Kofidis T, Woo CC, Lin XY, Foo R, et al. Role of Vascular Smooth Muscle Cell Plasticity and Interactions in Vessel Wall Inflammation. Vol. 11, *Frontiers in Immunology*. 2020.
61. Badimon L, Padró T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Vol. 1, *European Heart Journal: Acute Cardiovascular Care*. 2012. p. 60–74.
62. Nakahara T, Dweck MR, Narula N, Pisapia D, Narula J, Strauss HW. Coronary Artery Calcification: From Mechanism to Molecular Imaging. Vol. 10, *JACC: Cardiovascular Imaging*. 2017. p. 582–93.
63. Shi X, Gao J, Lv Q, Cai H, Wang F, Ye R, et al. Calcification in Atherosclerotic Plaque Vulnerability: Friend or Foe? Vol. 11, *Frontiers in Physiology*. 2020.

64. Canfield AE, Sutton AB, Hoyland JA, Schor AM. Association of thrombospondin-1 with osteogenic differentiation of retinal pericytes in vitro. Vol. 109, *Journal of Cell Science*. 1996. p. 343–53.
65. Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI, O'Neill WC. Phosphate-induced vascular calcification: Role of pyrophosphate and osteopontin. Vol. 15, *Journal of the American Society of Nephrology*. 2004. p. 1392–401.
66. Otsuka F, Sakakura K, Yahagi K, Joner M, Virmani R. Has our understanding of calcification in human coronary atherosclerosis progressed? Vol. 34, *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2014. p. 724–36.
67. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. Vol. 15, *Journal of the American Society of Nephrology*. 2004. p. 2857–67.
68. Demer LL, Tintut Y. Vascular calcification: Pathobiology of a multifaceted disease. Vol. 117, *Circulation*. 2008. p. 2938–48.
69. Proudfoot D, Skepper JN, Shanahan CM, Weissberg PL. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Vol. 18, *Arteriosclerosis, Thrombosis, and Vascular Biology*. 1998. p. 379–88.
70. Reith S, Milzi A, Dettori R, Marx N, Burgmaier M. Predictors for target lesion microcalcifications in patients with stable coronary artery disease: an optical coherence tomography study. Vol. 107, *Clinical Research in Cardiology*. 2018. p. 763–71.
71. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, et al. Terminology for high-risk and vulnerable coronary artery plaques. Vol. 25, *European Heart Journal*. 2004. p. 1077–82.
72. Vergallo R, Crea F. Atherosclerotic Plaque Healing. Vol. 383, *New England Journal of Medicine*. 2020. p. 846–57.
73. Yun SH, Sim EH, Goh RY, Park JI, Han JY. Platelet activation: The mechanisms and potential biomarkers. Vol. 2016, *BioMed Research International*. 2016.
74. Osaki T, Ichinose A. [Current views of activating and regulatory mechanisms of blood coagulation]. Vol. 72, *Nihon rinsho. Japanese journal of clinical medicine*. 2014. p. 1206–11.
75. Libby P. Inflammation in atherosclerosis. Vol. 32, *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2012. p. 2045–51.
76. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Vol. 27, *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2007. p. 1687–93.